piboserod
Small moleculeexperimental
Piboserod is a selective 5-HT4 receptor antagonist which was marketed and manufactured by GlaxoSmithKline (GSK) under the trade name Serlipet for the management of atrial fibrillation and irritable bowel syndrome. In 2007 the Norwegian company Bio-Medisinsk Innovasjon AS (BMI) completed a clinical phase II study to investigate the effect of piboserod in patients with chronic heart failure. — Wikipedia
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2001 (NCT00041496)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Serotonin 4 (5-HT4) receptorANTAGONIST
HTR4 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1- Mol. weight
- 369.51 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPiboserod ↗
- ChEMBLCHEMBL356359 ↗
Also known as
- bpmdoic
- n-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide
- piboserod
- piboserod
- piboserod
- sb 207266
- sb-207266
- sb-207266
- sb-207266
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00421746 | Phase 2 | Jan 1, 2006 | Bio-Medisinsk Innovasjon, Smerud Medical Research Denmark, University of Copenhagen |
| NCT00041496 | Phase 2 | Nov 1, 2001 | GlaxoSmithKline |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bio-Medisinsk Innovasjon | For profit | 1 | 1 | 1 | 2006 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2001 |
| Smerud Medical Research Denmark | For profit | 1 | 0 | 1 | 2006 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2006 |
4 organizations
Page 1 / 1